Herceptin联合化疗对Her-2过度表达的转移性乳腺癌治疗的初步观察

The Preliminary Observation of Trastuzumab-based Combination Chemotherapy in Salvage Treatment of Her-2 Overexpressing in Metastatic Breast Cancer

摘要: 目的初步观察15例接受Herceptin联合Vinorelbine(NVB)等药物治疗Her-2过度表达的转移性乳腺癌的疗效和毒副作用。方法Herceptin初始剂量为4mg/kg,以后每周1次,剂量为2mg/kg,至少6周。NVB25mg/m2,iv,d1,5;DDP20mg/m2,d1~3,静脉点滴;5-Fu1.0/d持续静脉点滴6~12h,d1~3。每21d为1周期。结果总有效率为73%(9/15),其中CR6例(40.0%),PR5例(33%)。中位生存期为13个月;中位TTP未达到。主要毒性为Ⅲ~Ⅳ度粒细胞减少及继发性发热;未观察到明显心脏毒性。结论Herceptin联合化疗作为Her-2过度表达的转移性乳腺癌的解救方案疗效显著,安全可靠。

Abstract: Objective To observe the effects and toxicity of trastuzumab-based combination regimen comprising vinorelbine,fluorouracil and cisplatin in 15 patients with Her-2 positive metastatic breast cancer. Methods Treatment consisted of Trastuzumab(4mg/kg on day 0,then 2mg/kg weekly);vinorelbine (25mg/m2 on day 1 and 5);cisplantin(20mg/m2 on day 1～3) and fluorouracil (5-Fu) 1.0 on day 1～3. Results The overall response rate was 73%,including 6 complete( 40.0%) and 5 partial responses(33%).Median survival was 13 months...